-
Increasing awareness of the need for brain health Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 The Lancet Neurology
-
Getting inside the head of Edinburgh Fringe performers Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Peter Ranscombe
-
-
Cristina Tassorelli: making a difference in headache research Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Udani Samarasekera
-
Detection of atrial fibrillation in patients after stroke – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Luciano A Sposato, Jason G Andrade, Thalia S Field
-
New therapeutic avenues for Duchenne muscular dystrophy Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Janbernd Kirschner
-
Pragmatic solutions for the global burden of stroke – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Valery L Feigin, Joseph Yaria, Mayowa Owolabi
-
Implications of the KIWE trial for low-income and lower-middle-income countries – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 J Helen Cross, Natasha E Schoeler, Louise Marston, Nick Freemantle, KIWE investigators
-
-
Implications of the KIWE trial for low-income and lower-middle-income countries Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Jitendra Kumar Sahu, Priyanka Madaan, Jithangi Wanigasinghe, Pauline Samia, South Asia allied IESS Research Group, Aye Mya Min Aye, Esmatullah Hamed, Kanij Fatema, Kyaw Linn, Mimi L Mynak, Nicolás Garófalo Gómez, Prakash Poudel, Prem Chand, Samaahath Hassan
-
Dysphagia after stroke: research advances in treatment interventions Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Bendix Labeit MD, Emilia Michou PhD, Michaela Trapl-Grundschober PhDr, Prof Sonja Suntrup-Krueger MD, Paul Muhle MD, Prof Philip M Bath FMedSci, Rainer Dziewas MD
After a stroke, most patients have dysphagia, which can lead to aspiration pneumonia, malnutrition, and adverse functional outcomes. Protective interventions aimed at reducing these complications remain the cornerstone of treatment. Dietary adjustments and oral hygiene help mitigate the risk of aspiration pneumonia, and nutritional supplementation, including tube feeding, might be needed to prevent
-
Detection of atrial fibrillation in patients after stroke Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Konstantinos C Siontis, Peter A Noseworthy, Paul A Friedman
-
Pragmatic solutions for the global burden of stroke Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Mathias Schlögl, Terence J Quinn, International Stroke Recovery and Rehabilitation Alliance (SRRRA) Frailty Stroke Group
-
Pragmatic solutions for the global burden of stroke Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Amit Kandel, Amit Arjyal, Biraj Karmacharya, Bikram Gajurel
-
Secondary stroke prevention in people with atrial fibrillation: treatments and trials Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Prof David J Seiffge MD, Virginia Cancelloni MD, Prof Lorenz Räber PhD, Maurizio Paciaroni MD, Prof Andreas Metzner MD, Prof Paulus Kirchhof MD FRCP, Prof Urs Fischer MD, Prof David J Werring PhD FRCP, Prof Ashkan Shoamanesh MD FRCPC, Prof Valeria Caso MD
Atrial fibrillation is one of the most common cardiac arrhythmias and is a major cause of ischaemic stroke. Recent findings indicate the importance of atrial fibrillation burden (device-detected, subclinical, or paroxysmal and persistent or permanent) and whether atrial fibrillation was known before stroke onset or diagnosed after stroke for the risk of recurrence. Secondary prevention in patients
-
Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Prof Eugenio Mercuri MD, Prof Juan J Vilchez MD, Prof Odile Boespflug-Tanguy MD, Craig M Zaidman MD, Prof Jean K Mah MD, Nathalie Goemans MD, Prof Wolfgang Müller-Felber MD, Erik H Niks MD, Prof Ulrike Schara-Schmidt MD, Enrico Bertini MD, Prof Giacomo P Comi MD, Prof Katherine D Mathews MD, Prof Laurent Servais MD, Krista Vandenborne PhD, Jessika Johannsen MD, Prof Sonia Messina MD, Stefan Spinty
Duchenne muscular dystrophy, the most common childhood muscular dystrophy, is caused by dystrophin deficiency. Preclinical and phase 2 study data have suggested that givinostat, a histone deacetylase inhibitor, might help to counteract the effects of this deficiency. We aimed to evaluate the safety and efficacy of givinostat in the treatment of Duchenne muscular dystrophy. This multicentre, randomised
-
Genetics of migraine: complexity, implications, and potential clinical applications Lancet Neurol. (IF 48.0) Pub Date : 2024-03-18 Heidi G Sutherland PhD, Bronwyn Jenkins BMed, Prof Lyn R Griffiths PhD
Migraine is a common neurological disorder with large burden in terms of disability for individuals and costs for society. Accurate diagnosis and effective treatments remain priorities. Understanding the genetic factors that contribute to migraine risk and symptom manifestation could improve individual management. Migraine has a strong genetic basis that includes both monogenic and polygenic forms
-
Fluctuations in Parkinson's disease: progress and challenges Lancet Neurol. (IF 48.0) Pub Date : 2024-03-15 Francisco Cardoso, Eduardo Tolosa
-
Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial Lancet Neurol. (IF 48.0) Pub Date : 2024-03-15 Prof Alberto J Espay MD, Prof Fabrizio Stocchi MD, Prof Rajesh Pahwa MD, Prof Alberto Albanese MD, Aaron Ellenbogen MD, Prof Joaquim J Ferreira MD, Prof Nir Giladi MD, Tanya Gurevich MD, Sharon Hassin-Baer MD, Jorge Hernandez-Vara MD, Stuart H Isaacson MD, Prof Karl Kieburtz MD, Prof Peter A LeWitt MD, Lydia Lopez-Manzanares MD, Prof C Warren Olanow MD, Prof Werner Poewe MD, Harini Sarva MD, Tami Yardeni
Conventional oral levodopa therapy for the treatment of Parkinson's disease can be associated with variations in plasma concentrations. Levodopa infusion strategies might provide more consistent drug delivery and fewer motor fluctuations. We aimed to assess the safety and efficacy of a continuous 24 h/day subcutaneous infusion of ND0612 (a levodopa–carbidopa solution) compared with oral immediate-release
-
The expanding burden of neurological disorders Lancet Neurol. (IF 48.0) Pub Date : 2024-03-14 Wolfgang Grisold
-
Addressing neurological burden in the Americas Lancet Neurol. (IF 48.0) Pub Date : 2024-03-14 Amy Tausch, Kiran T Thakur, Renato Oliveira e Souza
-
Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Lancet Neurol. (IF 48.0) Pub Date : 2024-03-14 GBD 2021 Nervous System Disorders Collaborators, Jaimie D Steinmetz, Katrin Maria Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Ewerton Cousin, Hailey Hagins, Madeline E Moberg, Max L Mehlman, Yohannes Habtegiorgis Abate, Jaffar Abbas, Madineh Akram Abbasi, Mohammadreza Abbasian, Hedayat Abbastabar, Michael Abdelmasseh, Mohammad Abdollahi, Mozhan Abdollahi,
-
-
-
Potential treatment targets for migraine: emerging options and future prospects Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Chia-Chun Chiang, Frank Porreca, Carrie E Robertson, David W Dodick
-
Sleep matters in anti-LGI1 encephalitis Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Anna Heidbreder
-
Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Amaia Muñoz-Lopetegi, Mar Guasp, Laia Prades, Eugenia Martínez-Hernández, Mireia Rosa-Justícia, Víctor Patricio, Thaís Armangué, Lorena Rami, Roger Borràs, Josefina Castro-Fornieles, Albert Compte, Carles Gaig, Joan Santamaria, Josep Dalmau
-
-
-
Thank you to The Lancet Neurology's peer reviewers in 2023 Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15
-
For a dementia diagnosis, clinical acumen must precede biomarkers Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 David S Knopman
-
The predictive value and clinical use of the neurological pupillary index Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Michael TC Poon, Ahmed Nouby, Paul M Brennan
-
Biomedical research must change as the climate does Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Grace Lindsay
-
The cultural history of dementia Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Hollie Sherwood-Martin
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Ramon Diaz-Arrastia, Francis Bernard, Lori Shutter, William Barsan, Robert Silbergleit
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Randall M Chesnut, Robert H Bonow, Walter Videtta
-
Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Jeremy Chataway, Thomas Williams, Vivien Li, Ruth Ann Marrie, Daniel Ontaneda, Robert J Fox
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Nathan Beucler
-
-
-
A future treatment horizon for migraine? Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Debbie L Hay
-
-
Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Pushpa Narayanaswami, Donald B Sanders, Laine Thomas, Dylan Thibault, Jason Blevins, Rishi Desai, Andrew Krueger, Kathie Bibeau, Bo Liu, Jeffrey T Guptill, Vern C. Juel, Karissa L. Gable, Lisa D. Hobson-Webb, Janice M. Massey, Shruti Raja, C. Douglas Emmet, Yuebing Li, David Polston, Steven Shook, Debbie Hastings, Zaeem A. Siddiqi, Muhammed Abid Alvi, Haley Andonian, Michael Nicolle, Denise Hulley
-
Monitoring patients with severe traumatic brain injury – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Jean-Francois Payen, Tobias Gauss, Antoine Vilotitch, Pierre Bouzat
-
-
The postmenopausal brain: no silver bullet, but silver linings Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Riley Bove, Hannah Silverman, Claudia Valeggia
-
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Giovanni B Frisoni, Cristina Festari, Federico Massa, Matteo Cotta Ramusino, Stefania Orini, Dag Aarsland, Federica Agosta, Claudio Babiloni, Barbara Borroni, Stefano F Cappa, Kristian S Frederiksen, Lutz Froelich, Valentina Garibotto, Alexander Haliassos, Frank Jessen, Anita Kamondi, Roy PC Kessels, Silvia D Morbelli, John T O'Brien, Markus Otto, Armand Perret-Liaudet, Francesca B Pizzini, Mathieu
-
-
Karen Duff: blazing a path in dementia research Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Priya Venkatesan
-
-
Monitoring patients with severe traumatic brain injury Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Nicolas Engrand, Loïc Miry
-
PROMISE of low-cost immunosuppressants for myasthenia gravis Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Sithara Ramdas, Jacqueline Palace
-
-
The predictive value and clinical use of the neurological pupillary index – Authors' reply Lancet Neurol. (IF 48.0) Pub Date : 2024-02-15 Stefania Galimberti, Matteo Petrosino, Paola Rebora, Mauro Oddo, Fabio S Taccone, Giuseppe Citerio
-
Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial Lancet Neurol. (IF 48.0) Pub Date : 2024-02-13 Prof Cristina Tassorelli MD, Krisztián Nagy MD, Patricia Pozo-Rosich MD, Michel Lanteri-Minet MD, Sara Sacco MD, Tomáš Nežádal MD, Hua Guo PhD, Rosa De Abreu Ferreira MD, Giovanna Forero MA, Joel M Trugman MD
Atogepant, an oral calcitonin gene-related peptide receptor antagonist, has been approved for the preventive treatment of migraine, but its efficacy and safety in people who have been failed by conventional oral preventive migraine treatments has not yet been evaluated in a dedicated clinical trial. The ELEVATE trial evaluated the safety, tolerability, and efficacy of atogepant for the preventive treatment
-
ELEVATEd hope for patients after migraine treatment failure Lancet Neurol. (IF 48.0) Pub Date : 2024-02-13 Xiaonuo Xu, Liang Dong, Jiying Zhou
-
-
Brain capital is crucial for global sustainable development Lancet Neurol. (IF 48.0) Pub Date : 2024-01-24 Harris A Eyre, William Hynes, Rym Ayadi, Facundo Manes, Pawel Swieboda
Abstract not available
-
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study Lancet Neurol. (IF 48.0) Pub Date : 2024-01-24 Ralf Reilmann, Karen E Anderson, Andrew Feigin, Sarah J Tabrizi, Blair R Leavitt, Julie C Stout, Paola Piccini, Robin Schubert, Pippa Loupe, Anna Wickenberg, Beth Borowsky, Gail Rynkowski, Rita Volkinshtein, Thomas Li, Juha-Matti Savola, Michael Hayden, Mark Forrest Gordon
Background Laquinimod modulates CNS inflammatory pathways thought to be involved in the pathology of Huntington's disease. Studies with laquinimod in transgenic rodent models of Huntington's disease suggested improvements in motor function, reduction of brain volume loss, and prolonged survival. We aimed to evaluate the safety and efficacy of laquinimod in improving motor function and reducing caudate
-
WHO considers multiple sclerosis treatments essential Lancet Neurol. (IF 48.0) Pub Date : 2024-01-22 Joanna Laurson-Doube, Anne Helme, Francesco Nonino, Thomas Piggott, Nick Rijke, Deanna Saylor
Abstract not available